NDASUBCUTANEOUSPOWDER
Approved
Dec 2008
Lifecycle
Peak
Competitive Pressure
0/100
Clinical Trials
20
Mechanism of Action
antagonist. It binds reversibly to the pituitary GnRH receptors, thereby reducing the release of gonadotropins and consequently testosterone.
Indications (1)
Clinical Trials (5)
Study of Radiation Therapy in Combination With Darolutamide + Degarelix in Intermediate Risk Prostate Cancer
Started Jul 2024
208 enrolled
Prostate Cancer
Non-fucosylated Anti-CTLA-4 (BMS-986218) + Degarelix Acetate vs. Degarelix Acetate Alone in Men With High-risk Localized Prostate Cancer
Started Feb 2020
26 enrolled
Prostate Cancer
FIRMAGON® Intensive Drug Monitoring
Started Aug 2019
1,454 enrolled
Prostate Cancer
Observational Prospective Study Describing the Global Patient Care and Follow-up of Prostate Cancer Patients Treated With Degarelix
Started Jun 2017
150 enrolled
Prostate Cancer
Phase IV Study to Evaluate Bone Mineral Density in No-bone Metastatic Prostate Cancer Treated With Degarelix
Started Jun 2017
35 enrolled
Prostate Cancer
Loss of Exclusivity
LOE Date
Apr 27, 2032
74 months away
Patent Expiry
Apr 27, 2032